Gender-related differences among patients with STEMI: a propensity score analysis

Francesco Tomassini,a,◊ Enrico Cerrato,a,*,◊ Cristina Rolfo,a Matteo Bianco,b Luca Lo Savio,c Alicia Quirós,d,e Mauro Echavarría-Pinto,f Sara Giolitto,d Emanuele Tizzani, Antonella Corleto,c Giorgio Quadri,a Rosario Tripodi,c Davide Minniti,g and Ferdinando Varbella,a

a Divisione di cardiologia intervenzionale, Ospedale degli Infermi, Rivoli and Ospedale Universitario San Luigi Gonzaga, Orbassano, Turin, Italy
b Divisione di Cardiologia, Ospedale Universitario San Luigi Gonzaga, Orbassano, Turin, Italy
c Divisione di Cardiologia, Ospedale degli Infermi, Rivoli, Turin, Italy
d Unidad de Cardiología Intervencionista, Hospital Clínico San Carlos, Madrid, Spain
e Departamento de Matemáticas, Universidad de León, Spain
f Departamento de Cardiología, Hospital General ISSSTE, Querétaro, Mexico
g Direzione Sanitaria, Ospedale degli Infermi, Rivoli, Italy

ABSTRACT

Introduction and objectives: Female sex is believed to be a significant risk factor for mortality among patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary interventions (pPCI).

Methods: We collected data on all consecutive STEMI patients treated with pPCI within 12 hours and compared the males vs the females. The primary endpoint was long-term mortality one month after hospital discharge. The secondary endpoint was 30-days mortality.

Results: From March 2006 to December 2016, 1981 patients underwent pPCI at our hospital, 484 (24.4%) were females. Compared with men, women were older (mean age 71.3 ± 11.6 vs 62.9 ± 11.8 years, P < .001), less smokers (26.7% vs 72.7%; P < .001), more diabetic (28.0% vs 22.3%; P < .002), more hypertensive (69.6% vs 61.3%; P < .001), presented more often with shock at baseline (13.2% vs 9.0%; P = .006), had longer symptoms-to-balloon time frames (5.36 ± 3.97 vs 4.47 ± 3.67 hours; P < .001). Also, women were less likely to receive glycoprotein IIb-IIIa inhibitors (59.5% vs 71.4%; P < .001) and stents (79.5% vs 86.6%; P = .01). During the 30-day and long-term follow-up [mean 4.9 ± 3.2 years] the female sex was associated with a higher mortality rate (8.9% vs 4.0%, P < .001 and 23.8% vs 18.4%, P = .01, respectively). After propensity score matching, 379 men and 379 women were selected. Female sex continued to be associated with a higher death rate at 30 days (9.5% vs 5.5%; P = .039) but not in the long term among survivors (25.6% vs 21.4%; P = .170).

Conclusions: Compared to men, women with STEMI undergoing pPCI had higher 30-day mortality rates. However, among survivors, the long-term mortality rate was similar. Even if residual confounding cannot be ruled out, this difference in the outcomes may be partially explained by biological sex-related differences.

Keywords: ST-segment elevation myocardial infarction. Primary angioplasty. Sex differences. Outcomes.

Diferencias relacionadas con el sexo en pacientes con IAMCEST: análisis por puntuación de propensión

RESUMEN

Introducción y objetivos: El sexo femenino se considera un importante factor de riesgo de mortalidad en el infarto agudo de miocardio con elevación del segmento ST (IAMCEST) tratado con intervención coronaria percutánea primaria (ICPP).

Métodos: Se analizó a todos los pacientes consecutivos con IAMCEST tratados con ICPP dentro de las primeras 12 horas, y se compararon varones y mujeres. El objetivo principal fue la mortalidad a largo plazo en los supervivientes después del primer mes del alta, y el objetivo secundario fue la mortalidad a los 30 días.
INTRODUCTION

Primary percutaneous coronary interventions [pPCI] have proven superior to fibrinolytic therapy for the management of patients with ST-segment elevation myocardial infarction [STEMI] as becoming the treatment of choice in this field. However, the question of whether there are any prognostic differences between women and men is still under discussion. Yet despite the fact that in recent studies women exhibit higher mortality rates, it is not clear if these differences are associated with worse risk profiles or with a sex-related frailty. Indeed, some studies have not shown any significant relationships between sex and mortality in STEMI, even after adjusting for age and other risk factors. Actually, only a limited number of studies have described medium or long-term mortality outcomes and differences in the inclusion criteria (i.e., the entire acute coronary syndrome spectrum or only the STEMI subset) and in the therapeutic strategies (i.e., medical or intervention) might explain these different findings. The goal of this large, single-center registry was to assess whether in consecutive patients with STEMI undergoing pPCI there were any differences between men and women in the clinical, angiographic, procedural characteristics, and clinical outcome at 30 days or in the long-term.

METHODS

All consecutive patients admitted to our center between January 2006 and December 2016 with a diagnosis STEMI treated with pPCI within 12 hours of symptom onset were recruited. The baseline features (age, sex, burden of cardiovascular risk factors, time from symptoms onset to balloon) were collected along with the procedural characteristics (target vessel, site and type of lesion, pharmacological treatment, thrombus aspiration, type of stent). All interventions were performed following the actual standards of PCI, and the treatment choice was left at the discretion of the operator who performed the procedure. All patients were routinely treated with aspirin (325 mg upon arrival, and then 100 mg daily indefinitely), and an IV bolus of unfractionated heparin [5000 IU]. The use of bivalirudin (0.75 mg/kg and 1.75 mg/kg/h at least to the end of the procedure), or unfractionated heparin (100 U/kg or 60 U/kg if abciximab was used) or abciximab was left at the operator’s discretion. When used, the infusion of abciximab was extended for another 12 hours after the procedure. A loading dose of clopidogrel (600 mg), prasugrel (60 mg), or ticagrelor [180 mg] was administered before or immediately after the PCI, unless patients were already on chronic maintenance therapy, and then followed by a maintenance dose of clopidogrel [75 mg once a day], prasugrel [10 mg once a day], or ticagrelor [90 mg twice a day] for 12 months when possible. Repeated revascularization was only performed in the presence of symptom recurrence or proven ischemia related to the treated lesion.

Data on the 30-day follow-up were available for all patients at our center database. Information beyond the first month was collected through outpatient visits, telephone calls or by reviewing any available medical records to obtain the longer follow-up for each patient. All data were entered into a dedicated database.

The men vs women outcomes before and after the propensity score matching were compared. The primary endpoint was long-term mortality after hospital discharge. The secondary endpoint was 30-day mortality rate, 30-day and long-term Bleeding Academic Research Consortium bleeding type ≥ 2.7 Long-term events were evaluated starting from day 31 after discharge until the longer available follow-up. The rate of procedural efficiency [defined a Thrombolysis in Myocardial Infarction [TIMI] III grade flow and residual stenosis < 30%] and ST-segment resolution of more than 50% 60–90 minutes after the PCI was also collected and reported.

Statistical analysis

Quantitative variables were expressed as mean ± standard deviation or median [Q1-Q3], according to the normality of their distribution. Qualitative variables were expressed as frequencies and percentages. The Fisher’s exact test or the chi-square test were used for qualitative variables while the Student’s t test or the Mann-Whitney U test were used for quantitative variables as appropriate. Survival data were represented and analyzed using the Kaplan-Meier curves and the Cox regression analysis. All statistical tests were 2-sided. Results were considered significant if P values < .05. Given the baseline differences between female and male patients and in order to reduce selection bias, we used propensity score matching. The logistic regression model was used based on the baseline and peri-percutaneous coronary intervention characteristics. Thus, P values < .20 were defined to include the selected variables in the final model. The selected variables were
Compared to men, women were older (mean age 71.3 ± 11.6 vs 65.0 ± 12.3 years, \( P = .039 \) and 4.2% vs 1.6%, \( P = .007 \)). Conversely, in the matched pairs, women had lower rates of hospitalization (13.2% vs 9.0%, \( P = .006 \)). They also had longer symptoms-to-balloon time (5.36 ± 3.97 vs 4.47 ± 3.67 hours, \( P = .007 \)). Also, as shown on table 2, women were less likely to be treated with glycoprotein IIb-IIIa inhibitors (59.5% vs 62.9%, \( P = .01 \)), thrombus aspiration devices (48.3% vs 58.0%, \( P = .01 \)), and they presented more frequently with cardiogenic shock at admission (13.2% vs 9.0%, \( P = .06 \)). They also had longer symptoms-to-balloon time (5.36 ± 3.97 vs 4.47 ± 3.67 hours, \( P = .007 \)). Also, as shown on table 2, women were less likely to be treated with glycoprotein IIb-IIIa inhibitors (59.5% vs 71.4%, \( P < .001 \) and 60.0% vs 65.8%, \( P = .033 \), respectively, and table 3).

At the 30-day and long-term follow-up (mean 4.9 ± 3.2 years, completed in 1634, 82.5% patients) the female sex was associated with a higher mortality rate (8.9% vs 4.0%, \( P < .001 \) and 23.8% vs 18.4%, \( P = .01 \), respectively) and a higher rate of major bleedings at 30 days (4.5% vs 1.4%, \( P = .007 \)).

After propensity score matching, 379 men and 379 women were selected. The baseline and peri-procedural characteristics of the propensity-matched pairs were identical (table 1, table 2, figure 1, table 3).
cohort no significant differences were found in the long-term mortality rate among survivors (25.6\% vs 21.4\%, \(P = .170\), table 3; and log-rank \(P = .23\), figure 3). The multiple Cox regression analysis revealed that age (hazard ratio [HR], 1.09 (1.06 – 1.12); \(P < .001\)), cardiogenic shock at presentation (HR, 6.82 (3.84 – 12.12); \(P < .001\)), the left ventricular ejection fraction < 35\% (HR, 1.98 (1.11 – 3.54); \(P = .022\)) and procedural efficacy (HR, 0.46 (0.23 – 0.89); \(P = .022\)) have an effect on mortality when included together with female sex (HR, 0.68 (0.42 – 1.09); \(P = .106\)), which is not significant as stated before (table 4).

Main outcome analysis was performed based on a 2-time period (2006-2010 and 2011-2016) without underlining any differences among the groups (table 2 of the supplementary data).

**DISCUSSION**

Our large single-center registry showed that in a high PCI volume center, women admitted with STEMI undergoing pPCI have a higher 30-day and long-term mortality rate compared to men. This difference persists after propensity score adjustment regarding the 30-day mortality.

A drop in cardiovascular mortality has been observed over the

Table 2. Angiographic and periprocedural features

<table>
<thead>
<tr>
<th></th>
<th>Raw</th>
<th>Matched</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Overall (n = 1981)</td>
<td>Female (n = 484); 24.4%</td>
</tr>
<tr>
<td>Multivessel disease</td>
<td>1055 (53.3)</td>
<td>259 (53.5)</td>
</tr>
<tr>
<td>Graft disease</td>
<td>6 (0.3)</td>
<td>2 (0.4)</td>
</tr>
<tr>
<td>Radial access</td>
<td>371 (18.7)</td>
<td>82 (16.9)</td>
</tr>
<tr>
<td>Use of GP IIb-IIIa</td>
<td>1357 (68.5)</td>
<td>288 (59.5)</td>
</tr>
<tr>
<td>Bivalirudin</td>
<td>210 (10.6)</td>
<td>61 (12.6)</td>
</tr>
<tr>
<td>Multivessel PCI</td>
<td>93 (4.7)</td>
<td>25 (5.2)</td>
</tr>
<tr>
<td>PCI on left main coronary artery</td>
<td>64 (3.2)</td>
<td>17 (3.5)</td>
</tr>
<tr>
<td>Aortic counterpulsation</td>
<td>251 (12.7)</td>
<td>69 (14.3)</td>
</tr>
<tr>
<td>Thrombus aspiration</td>
<td>1102 (55.6)</td>
<td>234 (48.3)</td>
</tr>
<tr>
<td>Stent implantation</td>
<td>1682 (84.9)</td>
<td>385 (79.5)</td>
</tr>
<tr>
<td>Drug-eluting stent implantation</td>
<td>832 (42.0)</td>
<td>194 (40.0)</td>
</tr>
</tbody>
</table>

GP, glycoprotein; PCI, percutaneous coronary intervention.

Values are expressed as mean ± standard deviation or frequencies (percentages).

Table 3. Outcomes

<table>
<thead>
<tr>
<th></th>
<th>Raw</th>
<th>Matched</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Overall (n = 1981)</td>
<td>Female (n = 484); 24.4%</td>
</tr>
<tr>
<td>Procedural efficacy</td>
<td>1903 (96.1)</td>
<td>450 (93.0)</td>
</tr>
<tr>
<td>ST-segment resolution &gt; 50%</td>
<td>1086 (64.4)</td>
<td>243 (60.0)</td>
</tr>
<tr>
<td>30-day BARC bleeding type ≥ 2</td>
<td>27 (2.1)</td>
<td>22 (4.5)</td>
</tr>
<tr>
<td>Long-term BARC bleeding type ≥ 2</td>
<td>41 (2.1)</td>
<td>21 (4.3)</td>
</tr>
<tr>
<td>30-day mortality rate</td>
<td>103 (5.2)</td>
<td>43 (8.9)</td>
</tr>
<tr>
<td>Overall mortality at long-term follow-up</td>
<td>390 (19.7)</td>
<td>115 (23.8)</td>
</tr>
</tbody>
</table>

Values are expressed as frequencies (percentages).

BARC, Bleeding Academic Research Consortium.

**Table 4. Multiple regression analysis**

<table>
<thead>
<tr>
<th></th>
<th>HR (95%CI)</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex</td>
<td>0.66 (0.42 – 1.09)</td>
<td>.106</td>
</tr>
<tr>
<td>Age</td>
<td>1.09 (1.06 – 1.12)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Cardiogenic shock at presentation</td>
<td>6.82 (3.84 – 12.12)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Left ventricular ejection fraction &lt; 35%</td>
<td>1.98 (1.11 – 3.54)</td>
<td>.022</td>
</tr>
<tr>
<td>Procedural efficacy</td>
<td>0.46 (0.23 – 0.89)</td>
<td>.022</td>
</tr>
</tbody>
</table>

95\%CI, 95\% confidence interval; HR, hazard ratio.

Cox proportional hazard model for overall mortality at long term follow-up.
last few decades, but cardiovascular disease is still the leading cause of mortality in women worldwide. Cardiovascular mortality remains higher in women compared to men.\textsuperscript{5} So far, the reasons of this difference have been mainly justified by the higher prevalence of traditional risk factors (higher mean age, hypertension, diabetes, and renal failure) in the female cohort.\textsuperscript{5} Also, women who experience myocardial infarction often present with atypical symptoms like dyspnea, fatigue, nausea/vomiting and atypical chest pain, which can lead to delayed diagnosis and treatment.\textsuperscript{5}

Another factor associated with a higher mortality rate to be taken into account is represented by bleeding and mechanical complications, more common in women compared to men.\textsuperscript{9-11} Our study confirmed all these data: in our population, women were significantly older, with more traditional risk factors (except for smoking), longer ischemic time frames and higher-risk presentations. Also, they had a significantly higher rate of bleeding and mechanical complications.

After propensity score adjustment, our study showed that female sex was independently associated with 30-day but not long-term mortality. These findings are similar to those of a recent large meta-analysis led by Conrotto et al.,\textsuperscript{12} that included 98,778 patients (73,559 men and 25,219 women) and could be explained, at least in part, by the different pathophysiology of coronary disease in women: the rupture of the plaque surface, the leading cause of coronary occlusion in men, happens only in around 50% of women,\textsuperscript{13} the remaining percentage being represented by the erosion of the plaque,\textsuperscript{14} coronary spasm leading to thrombus generation,\textsuperscript{15} and spontaneous coronary artery dissection.\textsuperscript{16} Particularly spontaneous coronary artery dissection seems to play an important role in younger women (< 60 years of age) and is associated with a high rate of major adverse cardiac events.\textsuperscript{17} Therefore, these findings may explain why, in our population, women had lower rate of thrombus aspiration, use glycoprotein IIb-IIIa inhibitors, and stent implantation, which in turn may justify, along with the clinical features, the lower procedural success and ST-segment resolution observed in our study. These factors, associated with the higher rate of bleedings and mechanical complications and other psychological factors, like depression, more prevalent in women compared to men in the general population,\textsuperscript{18,19} may be phenotypes of a higher frailty in the female sex, and may definitely explain the worse outcomes, at least in the short-term. At long-term, other factors, like the lower in-stent restenosis rate and the resulting lower need for target vessel revascularization observed in women, and already shown in some studies,\textsuperscript{20-23} may explain the similar outcomes observed in the propensity score analysis.
None of the authors have declared any conflicts of interests related to the present article.

**Limitations**

This study has some important limitations; first, even though is a retrospective analysis, it is based on a prospective and dedicated database with propensity score matched analysis. Secondly, data are derived from a single center, which limits their applicability. For example, the use of drug-eluting stents was lower than it is actually is, mainly because the time frame of the study is wide. Actually, from 2006 to 2010 the percentage of drug-eluting stents was about 15% while during the second period (2011-2016), we found 65% of cases with drug-eluting stent implantation. Finally, due to the time frame of the data collection, most procedures were performed via femoral artery access, so we can assume that radial access could have lowered the rate of access bleeding complications, but we need further randomized studies targeted at the female population before being able to validate this hypothesis. However, this is probably a representative sample of an all-comers STEMI population who undergo pPCI in the real world.

**CONCLUSIONS**

In conclusion, in our single-center cohort of patients and after propensity score adjustment, women with STEMI undergoing pPCI seem to have a higher 30-day mortality rate but similar long-term outcomes after discharge compared to men. Even if residual confounding cannot be ruled out, this difference in the outcomes may be partially explained by biological sex-related differences.

**CONFLICT OF INTERESTS**

None of the authors have declared any conflicts of interests related to the present article.

**WHAT IS KNOWN ABOUT THE TOPIC?**

- Women have a higher ACS-related mortality rate but there is no consensus on whether to consider female sex as a risk factor of poor outcomes. This is due to the fact that many authors explain this sex difference by the atypical onset of symptoms in women and the lower recurrence to cath. lab procedures and angioplasties performed in females. However, only a limited number of studies have reported medium or long-term mortality results and even fewer studies have had clear inclusion criteria (ie, the entire acute coronary syndrome spectrum or only the STEMI subset) or reported on the treatment strategies used.

**WHAT DOES THIS STUDY ADD?**

- Our large single-center registry showed that in a high PCI volume center, women admitted with STEMI to undergo pPCI have a higher rate of 30-day and long-term mortality compared to men. This difference persisted even after propensity score adjustment on the the 30-day mortality, which may be justified by the higher frailty of the female sex, which could in turn explain the worse outcomes seen, at least, in the short-term.

**SUPPLEMENTARY DATA**

Supplementary data associated with this article can be found in the online version available at [https://doi.org/10.24875/RECIEC.M19000061](https://doi.org/10.24875/RECIEC.M19000061).

**REFERENCES**

Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation*. 2005;111:1611-1618.


